Advanced BioNutrition Corp. (ABN), a leader in developing functional nutrition technology to improve animal health and human nutrition, announced that it has received a $184,000 award from the MIPS (Maryland Industrial Partnerships) program to support a study on the use of probiotics to replace antibiotics for disease prevention in salmon.
Fish and shrimp diseases around the world cause billions of dollars in losses each year in the aquaculture industry, and overuse of antibiotics leads to the development of antibiotic-resistant bacteria.
"The work we are conducting under this MIPS grant fits exactly within ABN's mission of developing safe, healthy and sustainable solutions to problems in the aquaculture and agriculture industries," said David J. Kyle, president and CEO of ABN.
ABN's novel microencapsulation technology allows delivery of probiotics ('friendly' bacteria) directly to the site of activity in the animal gut, where they prevent the growth of pathogenic bacteria.
ABN will deliver bacteria that are safe and widely used in human applications to juvenile salmon to prevent disease. Such a probiotic approach could provide better growth and survival, while alleviating the need for antibiotic treatment.
Research under this project, titled 'Selective Administration of Non-Dairy Derived Lactic Acid Bacteria to Pre-Smolting Atlantic Salmon,' will be conducted by Dr. Steven G. Hughes of the University of Maryland Eastern Shore and Dr. Moti Harel of ABN.
About MIPS
MIPS, a program of the A. James Clark School of Engineering's Maryland Technology Enterprise Institute (MTECH), enables technology commercialization in Maryland through jointly funded university-company research and development projects. For more information about MIPS, please visit http://www.mips.umd.edu.
About ABN
Advanced BioNutrition is a leader in developing functional nutrition technology to improve animal health and human nutrition. The company is headquartered in Columbia, MD. www.abn-corp.com.
